BPC-157

BPC-I57 is believed to work through several mechanisms to support healing and tissue regeneration. One of its primary actions is promoting angiogenesis, the formation of new blood vessels. This increased blood flow can help deliver oxygen and nutrients to damaged tissues, facilitating repair and regeneration. BPC-I57 has also been shown to stimulate the production of collagen, a key protein in connective tissues such as tendons and ligaments.

Additionally, BPC-I57 may have anti-inflammatory properties, helping to reduce inflammation and oxidative stress in various tissues. This can create a more favorable environment for healing and may help alleviate pain associated with injuries or inflammatory conditions.

BPC-I57 has also demonstrated neuroprotective effects, potentially helping to protect and regenerate nerve cells. This may be beneficial in conditions involving nerve damage or degeneration.

Furthermore, BPC-I57 has been shown to interact with the nitric oxide (NO) system, which plays a role in various physiological processes, including blood vessel dilation and tissue repair. By modulating the NO system, BPC-I57 may help regulate blood flow and support healing processes.

While the exact mechanisms of action are still being researched, BPC-I57's potential to promote angiogenesis, collagen production, and tissue regeneration, along with its anti-inflammatory and neuroprotective properties, may contribute to its research relevance.

• BPC-I57 has been studied for its potential benefits in various health conditions. It may help accelerate wound healing, promote tissue regeneration, and support the repair of tendons, ligaments, and muscles. BPC-I57 has shown promise in studies of inflammatory bowel disease, potentially reducing inflammation and promoting healing in the gut.
• In animal studies, BPC-157 has been investigated in models of joint and tendon injury, including tendinitis and osteoarthritis models. It may also have neuroprotective properties, which could be beneficial in conditions involving nerve damage or degeneration.
• Additionally, BPC-I57's potential anti-inflammatory and antioxidant effects may help reduce oxidative stress and inflammation in various tissues, supporting overall health and recovery from injuries or chronic conditions.

This section describes laboratory handling. It is not clinical guidance, and no safety claim for human or veterinary administration is made or implied.

• Supplied lyophilized. Reconstituted peptide solutions have materially shorter working stability than the dry powder — prepare working aliquots and avoid repeated freeze-thaw cycles.

• Handle as a research chemical of undetermined hazard. Use gloves, eye protection and a laboratory coat.

• Storage temperature and, where applicable, reconstitution conditions are stated on the item specification sheet and the lot Certificate of Analysis, which take precedence over general guidance.

• Dispose of unused material and consumables in accordance with the institutional chemical waste policy.

For laboratory research use only. Not for human or veterinary use. Not a drug, food, cosmetic or dietary supplement.

BPC-I57 is a promising synthetic peptide derived from a protein found in gastric juice. Research has shown its potential to support healing processes, promote tissue regeneration, and reduce inflammation in various tissues. BPC-I57 may work by stimulating angiogenesis, collagen production, and modulating the nitric oxide system. It has been investigated in laboratory models of inflammatory bowel disease, joint and tendon injury, and skin wounds. Additionally, BPC-I57 has demonstrated neuroprotective properties and may help reduce oxidative stress. While more research is needed to fully understand its mechanisms of action and long-term safety in mammals, BPC-I57 continues to be a subject of interest for its potential research applications.

1. Vukojevic, Katarina et al. "Stable gastric pentadecapeptide BPC I57 and wound healing." Frontiers in pharmacology vol. 12 718147
2. Gwyer, Danielle et al. "Gastric pentadecapeptide body protection compound BPC I57 and its role in accelerating musculoskeletal soft tissue healing." Cell and tissue research vol. 383,3 (2021)
3. Kalogjera, Livije et al. "Stable Gastric Pentadecapeptide BPC I57 in the Therapy of the Nasal Mucosa, Periodontium, and Dry Eye Syndrome." Biomedicines vol. 10,12 3281. 7 Dec. 2022
4. Sikiric, Predrag et al. "Brain-gut Axis and Pentadecapeptide BPC I57: Theoretical and Practical Implications." Current neuropharmacology vol. 17,11 (2019)
5. Knezevic, Maro et al. "Stable Gastric Pentadecapeptide BPC I57 Therapy for Periodontitis in Rats." Biomedicines vol. 10,4 859. 6 Apr. 2022
6. Kokot, Antonio et al. "Stable Gastric Pentadecapeptide BPC I57 Therapy for Primary Abdominal Compartment Syndrome in Rats." Frontiers in pharmacology vol. 13 861711. 18 Feb. 2022
7. Knezevic, Maro et al. "Stable Gastric Pentadecapeptide BPC I57 and Periodontal Healing in Rats." Biomedicines vol. 10,2 265. 25 Jan. 2022
8. Sever, Marko et al. "Stable Gastric Pentadecapeptide BPC I57 Therapy for Periodontitis in Rats." Biomedicines vol. 9,7 774. 29 Jun. 2021
9. Sikiric, Predrag et al. "Stable Gastric Pentadecapeptide BPC I57-NO-system Relation." Current pharmaceutical design vol. 26,25 (2020)
10. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC I57 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol (1985). 2011 Mar;110(3):774-80. doi: 10.1152/japplphysiol.00945.2010. Epub 2010 Oct 28. PMID: 21030672